Prostate Cancer Clinical Trials in San Antonio

Showing 101-120 of 231 trials

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

NCT02663193

The purpose of this study is to characterize the tolerability profiles of enzalutamide and abiraterone acetate (with prednisone) -with specific focus on central nervous system (CNS) tolerability-and quality of life (QoL) after approximately 2 months of participants starting treatment with one of these agents for metastatic castration-resistant prostate cancer (mCRPC).

Prostate Cancer

Janssen Scientific Affairs, LLC108 participantsStarted Dec 2015

Homewood, Alabama, United States • La Mesa, California, United States • Wheat Ridge, Colorado, United States +17 more locations

Active Not RecruitingPhase 3< 1 mile

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival and/or the radiographic progression free survival of study participants.

Prostate Cancer

AstraZeneca1,035 participantsStarted Mar 2022

Yuma, Arizona, United States • Beverly Hills, California, United States • Cerritos, California, United States +214 more locations

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer Trials in Other Cities

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Stockholm3 Validation Study in a Multi-Ethnic Cohort

PK and Dose Escalation and Expansion Study of DST-2970

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

Other Conditions in San Antonio